Zevra Therapeutics, Inc.

As of June 30, 2026, Zevra Therapeutics, Inc. carries a market capitalization of 759.58M, placing it among publicly traded companies globally. Its enterprise value stands at 566.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zevra Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Zevra Therapeutics, Inc. has 59.34M shares outstanding.

As of June 30, 2026, Zevra Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 14.46. The price-to-sales ratio is 6.19, and the price-to-book ratio stands at 3.99.

As of June 30, 2026, Zevra Therapeutics, Inc. trades at an EV/EBITDA multiple of 7.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.86 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Zevra Therapeutics, Inc. trades at an EV/FCF ratio of 17.31, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 566.95M versus a market cap of 759.58M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zevra Therapeutics, Inc. maintains a current ratio of 5.17, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.69, indicating moderate leverage, while an interest coverage ratio of 14.69 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zevra Therapeutics, Inc. posted a return on equity (ROE) of 34.80, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 33.03 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 20.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 31.64, useful for judging operating efficiency across full business cycles. The company generates approximately 1.97M in revenue per employee across its workforce of 60.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.47 indicates how many times Zevra Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zevra Therapeutics, Inc. recorded 9.65M in income tax expense. That works out to an effective tax rate of 15.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 60.65M, leaving 51.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Zevra Therapeutics, Inc.'s stock has gained approximately 3.11% over the past 52 weeks. The 50-day moving average sits at 9.93, while the 200-day moving average is 9.32.

Over the twelve months ended June 30, 2026, Zevra Therapeutics, Inc. generated 119.10M in revenue and converted that into 51.00M in net income, yielding earnings per share of 0.86. EBITDA reached 73.41M, while operating income came in at 34.20M.

As of June 30, 2026, Zevra Therapeutics, Inc. holds 193.94M in cash and equivalents against 1.31M in total debt, resulting in a net debt position of -127.20M. Total book value stands at 190.51M, with working capital of 177.40M providing operational flexibility.

Zevra Therapeutics, Inc. produced 29.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -678,357.50 in capital expenditures, free cash flow totaled 28.56M - equivalent to 0.50 per share.

Over the twelve months ended June 30, 2026, Zevra Therapeutics, Inc. posted a gross margin of 95.46, reflecting its pricing power and cost economics. The operating margin of 28.71 and net profit margin of 42.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.76, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.86, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zevra Therapeutics, Inc. shareholders.

Zevra Therapeutics, Inc.'s most recent stock split took place on December 28, 2020 with a 16:1 split ratio.

As of June 30, 2026, Zevra Therapeutics, Inc. has an Altman Z-Score of 6.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.